Breakdown | |||||
TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | Total Revenue | ||||
5.27M | 5.04M | 5.33M | 9.96M | 6.78M | 8.03M | Gross Profit |
2.11M | 2.08M | 2.03M | 154.00K | -1.93M | 2.83M | EBIT |
-6.06M | -3.65M | -13.87M | -19.40M | -35.53M | -21.59M | EBITDA |
-9.46M | -3.65M | -13.58M | -13.65M | -23.27M | -5.44M | Net Income Common Stockholders |
-5.83M | -7.04M | -13.98M | -15.61M | -16.13M | -6.03M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
2.83M | 4.24M | 11.64M | 20.64M | 28.68M | 25.67M | Total Assets |
9.54M | 13.52M | 19.70M | 28.92M | 43.92M | 47.35M | Total Debt |
14.56M | 155.00K | 1.01M | 2.02M | 3.29M | 9.35M | Net Debt |
11.73M | -4.09M | -5.51M | -18.63M | -25.39M | -4.69M | Total Liabilities |
26.84M | 7.29M | 7.00M | 8.02M | 12.72M | 18.80M | Stockholders Equity |
-17.30M | 6.22M | 12.84M | 21.03M | 31.09M | 27.73M |
Cash Flow | Free Cash Flow | ||||
-11.63M | -9.64M | -15.30M | -14.05M | -26.88M | -32.55M | Operating Cash Flow |
-11.56M | -9.63M | -15.29M | -13.98M | -25.87M | -30.22M | Investing Cash Flow |
4.88M | 7.34M | -4.34M | 1.42M | 16.61M | 17.28M | Financing Cash Flow |
-84.75M | 9.00K | 5.51M | 4.52M | 21.90M | 20.56M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
53 Neutral | $3.74M | ― | -68.97% | ― | -47.53% | 0.67% | |
51 Neutral | $4.01M | ― | -60.76% | ― | -6.20% | 64.07% | |
48 Neutral | $6.86B | 1.11 | -50.22% | 2.47% | 16.71% | 1.53% | |
47 Neutral | $4.11M | ― | -240.09% | ― | 97.84% | 82.99% | |
41 Neutral | $3.60M | ― | -103.63% | ― | -100.00% | 28.48% | |
35 Underperform | $3.89M | ― | -285.35% | ― | 674.14% | 89.05% | |
34 Underperform | $3.73M | ― | -91.62% | ― | ― | 48.81% |
Arcadia Biosciences announced a proposed all-stock business combination with Roosevelt Resources, a Texas-based partnership. This transaction aims to enhance their operational capabilities, with potential impacts on their market positioning and stakeholder interests. The companies held a webcast to discuss the transaction, which involves significant risks and uncertainties that could affect the final outcome. The success of the deal depends on several factors, including shareholder approvals and integration challenges.
Arcadia Biosciences and Roosevelt Resources have agreed to merge in an all-stock deal, making Roosevelt the majority shareholder. This strategic move aims to capitalize on Roosevelt’s vast oil and gas assets, particularly its carbon capture and storage project in Texas. The merger promises to enhance shareholder value and streamline operations, with Roosevelt’s experienced management leading the combined entity. The transaction is expected to close by Q1 2025, pending regulatory and shareholder approvals.